Maureen Macharia: How Apixaban Transformed Modern Anticoagulation
Maureen Macharia, Student at United States International University – Africa, shared a post on LinkedIn:
“Drug Spotlight: Apixaban
Blood clots can cause devastating complications such as stroke, deep vein thrombosis (DVT), and pulmonary embolism (PE).
Advances in anticoagulant therapy have made it possible to prevent these events by targeting specific components of the coagulation cascade.
Apixaban is a Direct Oral Anticoagulant (DOAC) that selectively inhibits Factor Xa, reducing thrombin generation and preventing the formation of harmful blood clots. Its predictable anticoagulant effect and lack of routine monitoring requirements have transformed the management of thromboembolic disorders.
- Prevents stroke and systemic embolism in patients with non valvular atrial fibrillation
- Used in the treatment and prevention of DVT and PE
- Reduces the risk of recurrent venous thromboembolism
- Fixed dose oral therapy with no routine INR monitoring required
What makes apixaban particularly interesting to me is how a single targeted action on Factor Xa can significantly reduce the risk of life-threatening thrombotic events.
It highlights the progress of modern pharmacotherapy from broad anticoagulation approaches to more selective, patient friendly treatments.
Studying apixaban reminds me that pharmacists play a critical role in balancing efficacy and safety, ensuring that patients are protected from both thrombosis and excessive bleeding.
This drug demonstrates how evidence based medicine can improve quality of life while reducing the burden of monitoring and hospital visits for patients.
Major adverse effect: Bleeding
Reversal agent: Andexanet alfa
‘Behind every dose of apixaban is an opportunity to prevent a stroke, preserve a life, and improve a patient’s future. Understanding its mechanism is not only about learning pharmacology it is about appreciating the impact that rational drug therapy has on patient outcomes.'”
Stay updated with Hemostasis Today.
-
Jul 23, 2026, 20:10Mohammad Alzoubi: One Month of Dual Antithrombotic Therapy After PCI Was Non-Inferior to 12 Months
-
Jul 23, 2026, 20:08Ahmed Bennis: Calcitriol Replenishment May Mitigate Ischemic Risk in MASLD
-
Jul 23, 2026, 20:06Mitsuaki Sawano: Can Cardiovascular Risk Prediction Models Developed in One Population be Reliably Applied to Another?
-
Jul 23, 2026, 20:05Abdul Muqtadir Abbasi: Hemostasis Isn’t About Memorizing Factor Numbers – It’s About Recognizing Patterns
-
Jul 23, 2026, 19:30Jordan Agay: Why We Need to Track the Neurological Costs of Anemia
-
Jul 23, 2026, 19:25William Archibald: Key Takeaways on VTE Cost-Effectiveness and Cancer Associated Thrombosis from ISTH 2026
-
Jul 23, 2026, 19:17Diego López Santos: Donation after Donation, I Just Reached 100
-
Jul 23, 2026, 19:11Jecko Thachil: Chlorosis May Have Represented Iron Deficiency in the 19th Century
-
Jul 23, 2026, 15:58Mel Snyder: Beyond Sickle Cell Disease to the Future of Pediatric Genetics